Annual Total Liabilities
$121.21 M
-$55.88 M-31.55%
December 31, 2024
Summary
- As of March 11, 2025, PBYI annual total liabilities is $121.21 million, with the most recent change of -$55.88 million (-31.55%) on December 31, 2024.
- During the last 3 years, PBYI annual total liabilities has fallen by -$107.82 million (-47.08%).
- PBYI annual total liabilities is now -51.55% below its all-time high of $250.17 million, reached on December 31, 2020.
Performance
PBYI Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$121.21 M
-$28.43 M-19.00%
December 31, 2024
Summary
- As of March 11, 2025, PBYI quarterly total liabilities is $121.21 million, with the most recent change of -$28.43 million (-19.00%) on December 31, 2024.
- Over the past year, PBYI quarterly total liabilities has dropped by -$28.43 million (-19.00%).
- PBYI quarterly total liabilities is now -57.90% below its all-time high of $287.88 million, reached on March 31, 2019.
Performance
PBYI Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
PBYI Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -31.6% | -19.0% |
| 3 y3 years | -47.1% | -30.3% |
| 5 y5 years | -44.3% | -30.3% |
PBYI Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -47.1% | at low | -47.1% | at low |
| 5 y | 5-year | -51.5% | at low | -53.8% | at low |
| alltime | all time | -51.5% | -100.0% | -57.9% | -100.0% |
Puma Biotechnology Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $121.21 M(-31.6%) | $121.21 M(-19.0%) |
| Sep 2024 | - | $149.63 M(-4.4%) |
| Jun 2024 | - | $156.49 M(-4.1%) |
| Mar 2024 | - | $163.17 M(-7.9%) |
| Dec 2023 | $177.09 M(-11.7%) | $177.09 M(+7.4%) |
| Sep 2023 | - | $164.86 M(-3.1%) |
| Jun 2023 | - | $170.09 M(-0.2%) |
| Mar 2023 | - | $170.41 M(-15.0%) |
| Dec 2022 | $200.45 M(-12.5%) | $200.45 M(+13.5%) |
| Sep 2022 | - | $176.62 M(+1.6%) |
| Jun 2022 | - | $173.91 M(-10.1%) |
| Mar 2022 | - | $193.54 M(-15.5%) |
| Dec 2021 | $229.03 M(-8.5%) | $229.03 M(-3.4%) |
| Sep 2021 | - | $237.21 M(+2.9%) |
| Jun 2021 | - | $230.53 M(-4.8%) |
| Mar 2021 | - | $242.22 M(-3.2%) |
| Dec 2020 | $250.17 M(+15.1%) | $250.17 M(-4.6%) |
| Sep 2020 | - | $262.15 M(+9.0%) |
| Jun 2020 | - | $240.41 M(+11.2%) |
| Mar 2020 | - | $216.15 M(-0.6%) |
| Dec 2019 | $217.44 M(-3.3%) | $217.44 M(+1.2%) |
| Sep 2019 | - | $214.86 M(-1.5%) |
| Jun 2019 | - | $218.09 M(-24.2%) |
| Mar 2019 | - | $287.88 M(+28.1%) |
| Dec 2018 | $224.82 M(+100.3%) | $224.82 M(+21.6%) |
| Sep 2018 | - | $184.81 M(-2.4%) |
| Jun 2018 | - | $189.32 M(+68.8%) |
| Mar 2018 | - | $112.18 M(-0.0%) |
| Dec 2017 | $112.22 M(+161.2%) | $112.22 M(+9.3%) |
| Sep 2017 | - | $102.69 M(+94.8%) |
| Jun 2017 | - | $52.71 M(+7.1%) |
| Mar 2017 | - | $49.23 M(+14.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2016 | $42.97 M(+27.0%) | $42.97 M(+0.2%) |
| Sep 2016 | - | $42.88 M(-2.1%) |
| Jun 2016 | - | $43.81 M(+8.9%) |
| Mar 2016 | - | $40.23 M(+18.9%) |
| Dec 2015 | $33.84 M(-26.0%) | $33.84 M(+26.3%) |
| Sep 2015 | - | $26.78 M(-2.9%) |
| Jun 2015 | - | $27.58 M(+0.1%) |
| Mar 2015 | - | $27.55 M(-39.7%) |
| Dec 2014 | $45.71 M(+124.2%) | $45.71 M(+50.1%) |
| Sep 2014 | - | $30.45 M(+4.9%) |
| Jun 2014 | - | $29.04 M(+35.3%) |
| Mar 2014 | - | $21.47 M(+5.3%) |
| Dec 2013 | $20.39 M(-10.5%) | $20.39 M(+0.2%) |
| Sep 2013 | - | $20.35 M(-2.9%) |
| Jun 2013 | - | $20.96 M(-7.8%) |
| Mar 2013 | - | $22.74 M(-0.2%) |
| Dec 2012 | $22.79 M(+2121.2%) | $22.79 M(-17.1%) |
| Sep 2012 | - | $27.49 M(+67.7%) |
| Jun 2012 | - | $16.40 M(+60.3%) |
| Mar 2012 | - | $10.23 M(+896.7%) |
| Dec 2011 | $1.03 M(>+9900.0%) | $1.03 M(>+9900.0%) |
| Sep 2011 | - | $0.00(-100.0%) |
| Jun 2011 | - | $3300.00(+37.5%) |
| Mar 2011 | - | $2400.00(>+9900.0%) |
| Dec 2010 | $0.00(-100.0%) | $0.00(0.0%) |
| Sep 2010 | - | $0.00(0.0%) |
| Jun 2010 | - | $0.00(0.0%) |
| Mar 2010 | - | $0.00(-100.0%) |
| Dec 2009 | $2300.00(+4.5%) | $2300.00(>+9900.0%) |
| Sep 2009 | - | $0.00(-100.0%) |
| Jun 2009 | - | $2300.00(+360.0%) |
| Mar 2009 | - | $500.00(-77.3%) |
| Dec 2008 | $2200.00 | $2200.00 |
FAQ
- What is Puma Biotechnology annual total liabilities?
- What is the all time high annual total liabilities for Puma Biotechnology?
- What is Puma Biotechnology annual total liabilities year-on-year change?
- What is Puma Biotechnology quarterly total liabilities?
- What is the all time high quarterly total liabilities for Puma Biotechnology?
- What is Puma Biotechnology quarterly total liabilities year-on-year change?
What is Puma Biotechnology annual total liabilities?
The current annual total liabilities of PBYI is $121.21 M
What is the all time high annual total liabilities for Puma Biotechnology?
Puma Biotechnology all-time high annual total liabilities is $250.17 M
What is Puma Biotechnology annual total liabilities year-on-year change?
Over the past year, PBYI annual total liabilities has changed by -$55.88 M (-31.55%)
What is Puma Biotechnology quarterly total liabilities?
The current quarterly total liabilities of PBYI is $121.21 M
What is the all time high quarterly total liabilities for Puma Biotechnology?
Puma Biotechnology all-time high quarterly total liabilities is $287.88 M
What is Puma Biotechnology quarterly total liabilities year-on-year change?
Over the past year, PBYI quarterly total liabilities has changed by -$28.43 M (-19.00%)